Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402604 | 0.89 | TNKS (0.43) | ADRA2CKEAP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13068325 | 0.78 | KEAP1 (0.39) | ADRA2CKEAP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13462411 | 0.78 | S1PR1 (0.37) | ADRA2CCYP2D6ADRA1AGAAMGLL | |
| SCHEMBL256749 | 0.78 | NOTUM (0.56) | SLC6A2SLC6A4SLC6A3GAAKDM4E | |
| SCHEMBL18373752 | 0.76 | KEAP1 (0.38) | ADRA2CKEAP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25044260 | 0.76 | KDM4E (0.35) | ADRA2CCYP2D6ADRA1AGAAMGLL | |
| SCHEMBL2625776 | 0.76 | NOTUM (0.57) | ADRA2CCYP2D6ADRA1AGAAKDM4E | |
| SCHEMBL94532 | 0.76 | DRD2 (0.46) | SLC6A2SLC6A4SLC6A3MGLLNOTUM | |
| SCHEMBL2625772 | 0.76 | NOTUM (0.57) | ADRA2CCYP2D6ADRA1AHTR2AADRA2A | |
| SCHEMBL21605177 | 0.76 | NOTUM (0.33) | ADRA2CCYP2D6ADRA1AGAAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| EP-2225236-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8829006-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| CN-1823063-B | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD | 2010-07-14 | — | — | CN | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| CN-1823063-A | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ADRA2C 65/4885KEAP1 2970/4885SLC6A2 1461/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | ADRA2C 158/4885KEAP1 2912/4885SLC6A2 445/4885 |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | ADRA2C 65/4885KEAP1 2970/4885SLC6A2 1461/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ADRA2C 65/4885KEAP1 2970/4885SLC6A2 1461/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | ADRA2C 4230/4885KEAP1 2328/4885SLC6A2 4049/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ADRA2C 65/4885KEAP1 2970/4885SLC6A2 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.